Mode
Text Size
Log in / Sign up

Necrotic alterations in paragangliomas are associated with higher metastasis rates and cardiovascular complicationsNecrotic Alterations Linked to Higher Metastasis in Paragangliomas

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that necrotic alterations in paragangliomas are associated with increased metastasis rates and cardiovascular risk.

This meta-analysis and retrospective study evaluate the clinical presentation and outcomes of patients with confirmed paragangliomas (PGLs), specifically comparing necrotic alterations to cystic alterations. The analysis included a single-center retrospective study of 103 patients and a meta-analysis involving 235 patients.

Key findings indicate that necrotic PGLs are associated with significantly higher metastasis rates compared to those without such lesions or with only cystic lesions (75% vs. 10% in the retrospective study; 16% vs. 4.5% in the meta-analysis). Additionally, tumors with necrotic alterations were larger (53.6 cm vs. 6.6 cm) and more frequently associated with cardiovascular complications (p < 0.0001). The prevalence of cystic alterations was reported at 61.8%, while necrotic alterations occurred in 3.9% of cases.

The authors note that the retrospective study was limited to a single center. While these findings suggest that identifying necrotic lesions may influence preoperative management and follow-up due to higher metastatic potential and cardiovascular risk, the data indicate an association rather than a confirmed causal link.

How this fits prior evidence

This finding addresses a gap in characterizing the clinical behavior of specific radiographic features in paragangliomas. While previous evidence noted that SDHD variant carriers have high penetrance and multifocal tumors but low metastasis and mortality, this study highlights how specific internal characteristics like necrosis may correlate with higher metastatic potential (16% vs. 4.5%) and cardiovascular risks.

Researchers looked at the differences between tumors with cystic changes and those with necrotic (dead tissue) changes in patients with paragangliomas. This research included a retrospective study of 103 patients and a meta-analysis involving 235 patients to compare how these different tumor types affected health outcomes.

The findings showed that tumors containing necrosis were associated with a much higher rate of metastasis. In one study, the metastasis rate was 75% for necrotic tumors compared to only 10% for others. These tumors also tended to be larger and were more frequently linked to cardiovascular complications.

Because these results come from a single-center retrospective study and a meta-analysis, they show an association rather than a direct cause. While the data suggests that identifying necrotic tissue could help doctors plan better care before surgery, it is important to remember that every patient's case is unique. Patients should discuss these specific findings with their medical team to understand how they apply to their own diagnosis.

What this means for you:
Tumors with necrotic tissue are linked to higher metastasis rates and more cardiovascular risks in paragangliomas.

Common questions

What is the risk of cancer spreading if a tumor has necrosis?

In one study, tumors with necrotic alterations showed a 75% metastasis rate compared to 10% in others. A separate meta-analysis also found a higher metastasis rate of 16% for necrotic tumors versus 4.5% for cystic ones. These figures show a link between tissue type and spread.

Are there heart risks associated with these types of tumors?

The meta-analysis found that tumors with necrotic alterations were more frequently associated with cardiovascular complications than those with only cystic alterations. This suggests that the presence of dead tissue may be linked to higher heart-related risks.

How does tumor size differ between these types?

The study found a significant difference in volume. Tumors with necrotic alterations measured an average of 53.6 cm, while those without such features were much smaller at 6.6 cm.

Study Details

Study typeMeta analysis
Sample sizen = 103
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
Paragangliomas (PGLs) are rare neural crest-derived tumors with highly variable morphology and clinical behavior. These tumors can present with cystic and necrotic alterations that may influence the clinical presentation of affected patients. However, prevalence and clinical significance of these pathological alterations remain poorly understood. In this retrospective study (2011-2021), 103 patients with confirmed PGLs were examined for cystic and necrotic alterations based on imaging and pathology reports as well as pathological re-evaluation. Cystic alterations, including microscopic, macroscopic, and pseudocystic alterations, were observed in 61.8% of PGLs. Regardless of their pathomorphological presentation, cystic alterations did not affect the clinical presentation of these patients. In contrast, necrotic alterations were identified in 3.9% of PGLs and were associated with a higher rate of metastasis (75% vs. 10%, p = 0.0124), larger tumor volume (53.6 cm vs. 6.6 cmp = 0.0339), and more pronounced signs and symptoms, including hypertension, palpitations, and weakness compared to patients without cystic/necrotic lesions. The prevalence of cystic and necrotic lesions was higher in adrenal than extra-adrenal PGLs. An additional meta-analysis of 235 patients with PGLs confirmed the increased rate of metastasis in necrotic PGLs (16% vs. 4.5%, p = 0.0369), which were also significantly more frequently associated with cardiovascular complications (p < 0.0001) than cystic PGLs. Considering pathological alterations, particularly necrotic lesions, may substantially affect the clinical management of patients with PGLs. Incorporating these features into preoperative management and follow-up strategies might be crucial, given the higher metastatic potential and increased cardiovascular risk associated with necrotic PGLs.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.